Atlas Trials

Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia

Clinical trial NCT01488929 · COMPLETED

Trial details

NCT number
NCT01488929
Sponsor
Targacept Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
SchizophreniaNegative SymptomsCognitive Dysfunction
Start date
2011-12-01
Primary completion
2013-11-01
Enrollment
603

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.